American Renal sets IPO price range

American Renal Associates Holdings Inc has set the terms of its pending IPO. American Renal plans to sell 7.5 million shares at a price range between $20 to $23 a share. The company’s stock plans to trade under the NYSE ticker “ARA.” Centerbridge Partners owns 79 percent of American Renal before the IPO, according to an SEC filing.

PRESS RELEASE

April 08, 2016 06:30 AM Eastern Daylight Time
BEVERLY, Mass.–(BUSINESS WIRE)–American Renal Associates Holdings, Inc. (“ARA”) today announced the launch of its initial public offering of 7,500,000 shares of newly issued common stock. The initial public offering price is currently estimated to be between $20 and $23 per share. ARA expects to grant the underwriters for the offering a 30-day option to purchase up to an additional 1,125,000 shares of ARA’s common stock at the initial public offering price. ARA’s common stock has been approved for listing on the New York Stock Exchange under the ticker symbol “ARA”.
BofA Merrill Lynch, Barclays and Goldman, Sachs & Co. are serving as lead joint book-running managers and as representatives of the underwriters for the offering. Wells Fargo Securities, LLC and SunTrust Robinson Humphrey are acting as joint book-running managers. Leerink Partners is acting as co-manager.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, email:dg.prospectus_requests@baml.com, Barclays Capital Inc., c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, email: Barclaysprospectus@broadridge.com or Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, email: prospectus-ny@ny.email.gs.com.
A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About American Renal Associates:
As of December 31, 2015, American Renal Associates Holdings, Inc. (ARA) operated 192 dialysis clinic locations in 24 states and the District of Columbia, treating over 13,000 patients with end stage renal disease. ARA operates exclusively through a physician joint venture model, in which it partners with 347 local nephrologists to develop, own and operate dialysis clinics.